Commercial Growth Tonix is a commercial-stage biotech with recent TONMYA launch for fibromyalgia and growing migraine product sales, signaling readiness for expanded field force coverage and channel partnerships to drive revenue in CNS and migraine segments.

Sales Expansion Headcount increased by 50 with plans to add 50 more sales reps by mid-Q3 2026, creating a sizable opportunity to onboard and train new reps to accelerate market penetration and improve payer access for TONMYA and related products.

Lyme and Vaccines Advancing infectious disease programs including TNX-4800 for Lyme disease prevention and TNX-801 for mpox/smallpox provides cross-sell potential with hospital and specialty channels, plus partnerships with public health and government programs.

Immunology Pipeline Immunology candidate TNX-1500 targeting kidney transplant rejection offers a potential B2B collaboration path with transplant centers and CROs, enabling early access programs and investigator-initiated studies to broaden pipeline exposure.

Financial Momentum Strong revenue growth in Q1 and Q2 2026 and substantial funding enable scale-up of field deployment, market access activities, and clinical expansion, presenting a compelling case to distributors, contract manufacturers, and strategic investors.